Digital interventions could help behaviour change, says NICEThe UK’s health watchdog has said health professionals can consider digital and mobile interventions as a supplement to Share XDigital interventions could help behaviour change, says NICEhttps://pharmaphorum.com/news/digital-interventions-could-help-behaviour-change-says-nice/
NHS patients denied new lung cancer drug after another NICE deadlockCertain untreated lung cancer patients on England’s NHS will have to make do with older drugs after NICE Share XNHS patients denied new lung cancer drug after another NICE deadlockhttps://pharmaphorum.com/news/nice-deadlock/
NICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCCNICE has been busy with announcements today, rejecting Astellas’ Xospata for a certain type of acute myeloid leukaemia Share XNICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCChttps://pharmaphorum.com/news/nice-rejects-astellas-xospata/
NICE backs Medtronic’s AF monitor in post-stroke patientsEngland’s NHS could prevent hundreds of strokes of unknown cause with a new implantable monitor that transmits data Share XNICE backs Medtronic’s AF monitor in post-stroke patientshttps://pharmaphorum.com/news/nice-backs-medtronics-af-monitor-in-post-stroke-patients/
Sanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and BrexitMarc Moodley has worked at Sanofi since 2018 and is the new medical head, UK and Ireland for Share XSanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and Brexithttps://pharmaphorum.com/views-analysis-oncology/sanofi-genzyme-uk-medical-boss-marc-moodley-discusses-oncology-plans-nice-and-brexit/
Akcea’s rare disease drug Waylivra way too pricey for NHS, says NICELess than a week into 2020 and NICE has provisionally ruled against NHS funding for another drug – Share XAkcea’s rare disease drug Waylivra way too pricey for NHS, says NICEhttps://pharmaphorum.com/news-market-access/akceas-rare-disease-drug-waylivra-way-too-pricey-for-nhs-says-nice/
NICE rejects Roche’s Tecentriq in new lung cancer useNICE has said in first draft guidance that Roche’s Tecentriq should not get regular NHS funding as a Share XNICE rejects Roche’s Tecentriq in new lung cancer usehttps://pharmaphorum.com/news/nice-rejects-roches-tecentriq-in-new-lung-cancer-use/
The 4 biggest pharma market access stories of 2019What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive Share XThe 4 biggest pharma market access stories of 2019https://pharmaphorum.com/views-analysis-market-access/the-4-biggest-pharma-market-access-stories-of-2019/
An alternative set of metrics for the UK’s pricing and access dealLeela Barham takes a look at alternative ways pharma and the UK government could measure progress for the Share XAn alternative set of metrics for the UK’s pricing and access dealhttps://pharmaphorum.com/views-and-analysis/an-alternative-set-of-metrics-for-the-uks-pricing-and-access-deal/
